SG11202008030WA - Kv7 channel activators compositions and methods of use - Google Patents

Kv7 channel activators compositions and methods of use

Info

Publication number
SG11202008030WA
SG11202008030WA SG11202008030WA SG11202008030WA SG11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA
Authority
SG
Singapore
Prior art keywords
methods
channel activators
compositions
activators compositions
channel
Prior art date
Application number
SG11202008030WA
Inventor
Michael E Bozik
Scott S Harried
Lynn Resnick
George T Topalov
Justin K Belardi
Charles A Flentge
David A Mareska
James S Hale
Original Assignee
Knopp Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knopp Biosciences Llc filed Critical Knopp Biosciences Llc
Publication of SG11202008030WA publication Critical patent/SG11202008030WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202008030WA 2018-03-19 2019-03-19 Kv7 channel activators compositions and methods of use SG11202008030WA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862644902P 2018-03-19 2018-03-19
US201862644932P 2018-03-19 2018-03-19
US201862663438P 2018-04-27 2018-04-27
US201862697198P 2018-07-12 2018-07-12
PCT/US2019/023039 WO2019183148A1 (en) 2018-03-19 2019-03-19 Kv7 channel activators compositions and methods of use

Publications (1)

Publication Number Publication Date
SG11202008030WA true SG11202008030WA (en) 2020-10-29

Family

ID=67905138

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202008030WA SG11202008030WA (en) 2018-03-19 2019-03-19 Kv7 channel activators compositions and methods of use

Country Status (13)

Country Link
US (4) US10851067B2 (en)
EP (1) EP3768677A4 (en)
JP (2) JP2021518844A (en)
KR (1) KR20200133259A (en)
CN (1) CN112771039A (en)
AU (3) AU2019239955B2 (en)
BR (1) BR112020018933A2 (en)
CA (1) CA3093976A1 (en)
IL (2) IL310136A (en)
MX (2) MX2020009693A (en)
NZ (1) NZ767228A (en)
SG (1) SG11202008030WA (en)
WO (1) WO2019183148A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9481653B2 (en) * 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
WO2019183148A1 (en) * 2018-03-19 2019-09-26 Knopp Biosciences Llc Kv7 channel activators compositions and methods of use
WO2021055538A1 (en) * 2019-09-17 2021-03-25 Knopp Biosciences Llc Methods of use for kv7 channel activators
WO2024050389A1 (en) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Combination therapies including metal channel activators and nmda receptor antagonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0772181B2 (en) 1989-06-26 1995-08-02 株式会社大塚製薬工場 Benzimidazole derivative
JPH0772181A (en) 1993-09-03 1995-03-17 Advantest Corp Potential waveform measurement method and device
GB9413724D0 (en) 1994-07-07 1994-08-24 Wellcome Found Therapeutic nucleosides
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
SE0301701D0 (en) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AR054045A1 (en) * 2005-05-18 2007-05-30 Neuraxon Inc BENZOIMIDAZOL COMPOUNDS REPLACED WITH NON-INHIBITORY DUAL ACTIVITY AND MU AGIOIST OPIOID
CN101516873A (en) * 2006-10-03 2009-08-26 神经研究公司 Indazolyl derivatives useful as potassium channel modulating agents
CN101778833A (en) 2007-08-10 2010-07-14 日本曹达株式会社 Nitrogen-containing heterocyclic compound and pest control agent
DK2409975T3 (en) 2007-11-22 2015-08-03 Zenyaku Kogyo Kk Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
EP2231661A1 (en) 2007-12-19 2010-09-29 Amgen, Inc. Inhibitors of pi3 kinase
WO2010051819A1 (en) 2008-11-10 2010-05-14 Neurosearch A/S Novel 2,3-diamino-quinazolinone derivatives and their medical use
EP2373163B1 (en) 2008-12-19 2015-06-10 Genentech, Inc. Heterocyclic compounds and methods of use
AU2011275393B2 (en) 2010-07-08 2014-04-10 Pfizer Inc. Piperidinyl pyrimidine amides as Kv7 potassium channel openers
MX2013001313A (en) 2010-08-05 2013-06-13 Amgen Inc Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase.
ES2885424T3 (en) * 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo (4,5-B) pyridin-2-yl amides as activators of the Kv7 channel
WO2015023958A1 (en) * 2013-08-15 2015-02-19 The University Of Kansas Toll-like receptor agonists
US9481653B2 (en) 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
WO2019183148A1 (en) * 2018-03-19 2019-09-26 Knopp Biosciences Llc Kv7 channel activators compositions and methods of use

Also Published As

Publication number Publication date
AU2019239955B2 (en) 2023-08-24
MX2023001153A (en) 2023-02-22
EP3768677A4 (en) 2021-12-22
US20190284142A1 (en) 2019-09-19
US11724990B2 (en) 2023-08-15
AU2019239955A1 (en) 2020-10-01
NZ767228A (en) 2023-11-24
US10851067B2 (en) 2020-12-01
IL277419A (en) 2020-11-30
CN112771039A (en) 2021-05-07
US20230000831A1 (en) 2023-01-05
CA3093976A1 (en) 2019-09-26
AU2023266373A1 (en) 2023-12-07
IL277419B1 (en) 2024-03-01
JP2021518844A (en) 2021-08-05
MX2020009693A (en) 2021-01-08
KR20200133259A (en) 2020-11-26
BR112020018933A2 (en) 2020-12-29
AU2023266373B2 (en) 2024-02-08
WO2019183148A1 (en) 2019-09-26
US20210130299A1 (en) 2021-05-06
AU2024202496A1 (en) 2024-05-09
EP3768677A1 (en) 2021-01-27
US11261162B2 (en) 2022-03-01
IL310136A (en) 2024-03-01
US20240002349A1 (en) 2024-01-04
JP2024026104A (en) 2024-02-28

Similar Documents

Publication Publication Date Title
GB2582482B (en) CASZ compositions and methods of use
IL280963A (en) Anti-gdf15 antibodies, compositions and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
IL277419A (en) Kv7 channel activators compositions and methods of use
EP3576782A4 (en) Construct-peptide compositions and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
SG11202106585UA (en) Polishing compositions and methods of using same
GB202105087D0 (en) Microbial compositions and methods of use
SG11202106584QA (en) Polishing compositions and methods of using same
SG11202011274YA (en) Chemical compositions and methods of using same
SG11202111672RA (en) Cancer associated antibody compositions and methods of use
SG11202011227VA (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
IL283782A (en) Anellosomes and methods of use
IL280000A (en) Tumor reduction formulations and methods of use thereof
ZA202000502B (en) Cosmetic compositions and methods of use
EP3843555A4 (en) Anthocyanin-based colorant compositions and methods of use thereof
GB2589398B (en) Compounds and methods of use
EP4081233A4 (en) Composition and methods of manufacture
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use
SG11202012283XA (en) Additive composition and method of preparing the same
SG11202011121UA (en) Dantrolene formulations and methods of their use
SG11202002351SA (en) Poloxamer compositions and methods of making and using same
IL291318A (en) Methods of use for kv7 channel activators